Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

123.51USD
26 Apr 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$123.51
Open
$123.79
Day's High
$124.26
Day's Low
$123.48
Volume
5,021,839
Avg. Vol
6,694,813
52-wk High
$129.00
52-wk Low
$109.32

Select another date:

UPDATE 1-Strong pharma unit drives Bayer earnings beat

* Shares indicated to rise 0.8 percent (Adds details on best-selling product Xarelto, share indication)

J&J, Takeda among interested in Brazil's Hypermarcas: sources

SAO PAULO Johnson & Johnson , Novartis AG and Takeda Pharmaceutical Co Ltd have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA , two people with knowledge of the matter said on Monday.

UPDATE 4-J&J, Takeda among interested in Brazil's Hypermarcas, sources say

SAO PAULO, April 24 Johnson & Johnson, Novartis AG and Takeda Pharmaceutical Co Ltd have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA , two people with knowledge of the matter said on Monday.

J&J, Novartis and Takeda in talks for Brazil's Hypermarcas, sources say

SAO PAULO, April 24 Johnson & Johnson, Novartis AG and Takeda Pharmaceutical Co Ltd are in talks with the controlling bloc of Brazilian drugmaker Hypermarcas SA for a buyout, two people with knowledge of the matter said on Monday.

J&J grabs 92.62 pct Actelion stake in provisional tender results

* Says Janssen Holding GmbH, a Swiss subsidiary of Johnson & Johnson, published the provisional notice of the end result of its all-cash public tender offer in Switzerland to acquire all publicly held shares of Actelion Ltd

FDA approves Samsung Bioepis' copy of J&J's Remicade: company

SEOUL South Korea's Samsung Bioepis Co Ltd said on Saturday the U.S. Food and Drug Administration approved its copy of Johnson & Johnson's rheumatoid arthritis drug Remicade, the first drug developed by the Samsung Group unit approved in the United States.

CORRECTED-U.S. FDA approves Samsung Bioepis' copy of J&J's Remicade - company

* Latecomer invested $1.3 bln in biosimilar development so far

BRIEF-BB Biotech posts Q1 net profit of 375 million Swiss francs

* Earned a bottom-line profit of 375 million Swiss francs ($375.45 million) in Q1 of 2017

J&J target Actelion could exit Swiss benchmark SMI index this month

ZURICH The composition of the top Swiss stock index is due to change as early as this month, with Actelion poised to fall out of the Swiss Market Index (SMI) ahead of the completion of the biotechnology company's takeover by Johnson & Johnson .

J&J target Actelion could exit Swiss benchmark SMI index this month

ZURICH, April 20 The composition of the top Swiss stock index is due to change as early as this month, with Actelion poised to fall out of the Swiss Market Index (SMI) ahead of the completion of the biotechnology company's takeover by Johnson & Johnson.

Select another date:

More From Around the Web